Pulse Biosciences, Inc. (NASDAQ: PLSE) is a Healthcare company (Medical - Instruments & Supplies) with a market capitalization of $3.3B. The Maz Rating grades it against the other companies in its sector.
Pulse Biosciences, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $44.84, Pulse Biosciences, Inc. trades at 2188.9x sales and 17.4x book value. Over the last twelve months it generated about $2M of revenue and a net loss of $89M. It runs a gross margin of 9.4%, an operating margin of -5821.1% and a net margin of -5603.9%. It shows return on equity of -77.9%, return on invested capital of -45.8% and a free cash flow yield of -1.9%. On the balance sheet: a debt-to-equity ratio of 0.03 and a current ratio of 14.35. Over the past 52 weeks the share price ranged from $12.56 to $58.94, with a beta of 1.64.
Pulse Biosciences, Inc. does not currently pay a dividend.
7 Wall Street analyst ratings cover the stock: 5 Buy and 2 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Pulse Biosciences, Inc. is an innovative firm specializing in bioelectric medicine. Their primary offering is the CellFX System, a sophisticated, console-based platform that is precisely controlled via software. This system utilizes its proprietary Nano-Pulse Stimulation technology to deliver extremely brief, nanosecond-duration electrical pulses. This advanced method is designed to selectively eliminate target cells without thermal damage, effectively safeguarding adjacent non-cellular tissue. The CellFX System is applied in the treatment of various medical conditions. The company, originally incorporated in 2014 as Electroblate, Inc., officially became Pulse Biosciences, Inc. in December 2015. Its corporate headquarters are situated in Hayward, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Pulse Biosciences, Inc. (PLSE) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 5.31% / 30% · Interest income / Revenue 305.1% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 5.31% / 33% · Receivables / Mkt Cap (36m) 0.01% / 49% · Interest income / Revenue 305.1% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 5.31% / 33.33% · Receivables / Mkt Cap (24m) 0.01% / 33.33% · Interest income / Revenue 305.1% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.00% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 89.2% / 33.33% · Receivables / Avg Assets (4Q) 0.21% / 33.33% · Interest income / Revenue 305.1% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 93.9% / 33.33% · (Cash+Recv) / Total Assets 94.1% / 33.33% · Interest income / Revenue 305.1% / 5% | Fail |
No. As of September 2026, Pulse Biosciences, Inc. (PLSE) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Pulse Biosciences, Inc. is over the AAOIFI limit on Interest income / Revenue.
About 305.1% of each dividend: Pulse Biosciences, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.